• Cy5 RNA Labeling Kit: From LLPS to Probe Design

  2026-08-07

  The Cy5 RNA labeling kit K1062 connects controllable fluorescent nucleotide incorporation with mechanistic studies of RNA–protein condensation. Learn how to translate SARS-CoV-2 nucleocapsid phase-separation findings into better probe design, controls, and imaging workflows.

• Cucurbitacin I (JSI-124): Advanced STAT3 Inhibition in Cance

  2026-08-07

  Cucurbitacin I (JSI-124) stands out for its highly selective STAT3 pathway inhibition, enabling researchers to dissect tumor proliferation and survival with precision tools. This guide delivers optimized protocols, troubleshooting advice, and cross-study insights for maximizing the compound’s impact in cancer and neuro-cardiac research models.

• Tetramethylrhodamine Ethyl Ester Perchlorate in Live Mitocho

  2026-08-06

  Tetramethylrhodamine ethyl ester perchlorate (TMRE) empowers real-time visualization of mitochondrial membrane potential with high sensitivity and minimal cytotoxicity, making it essential for interrogating mitochondrial dysfunction in disease models. This article demystifies TMRE's mechanism, offers optimized workflows, and translates new mechanistic insights into practical troubleshooting strategies for advanced mitochondrial fluorescence imaging.

• Topoisomerase I Regulates Satellite DNA Transcription in Euk

  2026-08-06

  The referenced study uncovers Topoisomerase I as an evolutionarily conserved regulator of α-satellite DNA transcription at centromeres, essential for chromosome segregation. This work clarifies mechanisms of non-coding satellite RNA production and its interplay with DNA damage responses, offering new insight for cancer and chromosome biology.

• β-Amanitin: Molecular Mechanisms and Assay Innovations in RN

  2026-08-05

  Discover the molecular intricacies of β-Amanitin as a selective RNA polymerase II inhibitor. This article explores advanced assay strategies, practical protocol guidance, and the latest innovations in detection, offering a distinctive perspective for transcriptional regulation research.

• AMG 487 and CXCR3 Antagonism: Redefining Macrophage Polariza

  2026-08-05

  AMG 487, a selective CXCR3 antagonist, is reshaping strategies for dissecting macrophage polarization and inflammatory regulation. This article integrates mechanistic insights from recent studies with actionable guidance for translational researchers, highlighting protocol parameters, workflow optimization, and translational relevance in inflammation and immune modulation models. The discussion situates AMG 487 within the evolving competitive landscape and lays a forward-looking vision for CXCR3-targeted research.

• CD40 and STING Competition Drives B Cell Activation in ESCC

  2026-08-04

  A recent study elucidates how CD40 and STING competitively bind TRAF2 to regulate IRF4-mediated B cell activation within tertiary lymphoid structures in esophageal squamous cell carcinoma (ESCC). This mechanistic insight refines our understanding of antitumor immunity and highlights new avenues for biomarker and therapeutic strategy development.

• GCG Disrupts SARS-CoV-2 Nucleocapsid LLPS to Inhibit Replica

  2026-08-04

  Zhao et al. elucidate how the SARS-CoV-2 nucleocapsid protein undergoes RNA-induced liquid–liquid phase separation (LLPS), a process critical for viral replication and assembly. The study demonstrates that (-)-gallocatechin gallate (GCG), a green tea polyphenol, can inhibit this LLPS and thereby suppress SARS-CoV-2 replication, offering new mechanistic insights and therapeutic leads.

• BipD-Driven Mitophagy Enables Burkholderia pseudomallei Evas

  2026-08-03

  A recent study uncovers how Burkholderia pseudomallei exploits the host's mitophagy pathway via its BipD protein, promoting intracellular survival. These findings advance understanding of bacterial manipulation of mitochondrial quality control, with significant implications for infection biology and autophagy assays.

• Malate ((S)-2-hydroxysuccinic acid): Protocols for TCA Cycle

  2026-08-03

  Malate, a central metabolic intermediate, empowers researchers to dissect mitochondrial and immunometabolic dynamics in disease models. This article delivers experimental workflows, troubleshooting strategies, and unique translational insights leveraging APExBIO’s validated malate for advanced TCA cycle and metabolic reprogramming assays.

• Difloxacin HCl: Advanced Workflows for Microbial and MDR Res

  2026-08-02

  Difloxacin HCl stands out as a quinolone antimicrobial antibiotic bridging robust antimicrobial susceptibility testing and multidrug resistance reversal. Explore optimized protocols, troubleshooting strategies, and experimental enhancements for both microbiology and oncology labs, all leveraging APExBIO’s high-purity research reagent.

• Optimizing Oxidative Stress Assays with 2',7'-Dichlorofluore

  2026-08-01

  This article delivers scenario-driven, evidence-based guidance for using 2',7'-Dichlorofluorescein diacetate (SKU C3381) in sensitive intracellular ROS assays. Drawing on validated workflows and current literature, we address real-world challenges in assay design, probe selection, and data interpretation, highlighting how APExBIO's formulation supports reproducible, quantitative oxidative stress measurement.

• EZ Cap™ Cy5 EGFP mRNA (5-moUTP): Precision mRNA Delivery Wor

  2026-07-31

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) empowers real-time, dual-fluorescence tracking of both mRNA delivery and protein translation, streamlining advanced gene regulation studies. Its immune-evasive and stability-enhancing design enables high-fidelity assays in challenging cell types, including macrophages.

• Strategic Targeting of IDH1-Mutant AML: AG-120 and Metabolic

  2026-07-31

  Explore how AG-120 (Ivosidenib) redefines translational research in IDH1-mutant AML by integrating mechanistic insights from CD44-driven metabolic rewiring. This article connects biochemical rationale, experimental protocols, and evolving clinical strategies, offering actionable guidance for overcoming resistance and optimizing differentiation therapies.

• Selective ClpP Activation Induces Cell Cycle Arrest in LUSC

  2026-07-30

  A recent study reveals that ZK53, a selective activator of human ClpP, triggers cell cycle arrest and inhibits lung squamous cell carcinoma (LUSC) by disrupting mitochondrial oxidative phosphorylation and activating ATM-mediated DNA damage response. These findings offer a new mechanistic perspective on mitochondrial proteostasis as a therapeutic target in LUSC and suggest experimental strategies for dissecting nuclear-mitochondrial signaling in cancer research.

14729 records 1/982 page Next 12345 下5页 Last page